Catalyst Pharmaceuticals (CPRX) 10-Q2009 Q3 Quarterly report

Filed: 12 Nov 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acuity, adhere, adjunctive, adult, advisor, agent, al, aminotransferase, amplified, ASC, benzoylecgonine, brain, branded, Brodieet, call, cardiovascular, central, Chairman, closed, closing, collected, combination, Committee, complex, compliant, composition, conclusion, Consolidated, counting, CPRX, Curhan, daily, damage, deducting, Defense, Denmark, discovered, encouraging, epilepsy, existence, expansion, extended, facilitate, Fast, Feinstein, finalized, Finally, Ford, foreign, forma, fourth, framework, GABA, group, higher, importance, inadequately, infantile, inThe, Island, Jack, Jewish, key, lead, led, LIJ, long, low, Lundbeck, manner, Medicine, Merriman, met, metabolite, methodology, milestone, Miller, Mitigation, motivating, moved, newly, North, Northwestern, observed, October, opiate, Opioid, Ovation, oversaw, partial, Patrick, pending, placement, poor, portfolio, potent, power, powered, President, pro, profile, program, Project, pronouncement, properly, prove, refractory, Renshaw, request, response, responsibility, responsible, returned, review, Rodman, role, Sabril, sample, Schiffer, School, secretary, Shore, side, size, Steven, subsidiary, substance, suggest, supply, symbol, system, table, targeting, team, therapy, tolerated, Track, transfer, transferred, Treasurer, trend, University, unmet, unused, upfront, urine, usage, variety, Vice, voluntarily, week, Weinstein, wide, worldwide, Wynne, York

Removed: accounted, acquisition, addictive, alcohol, annually, beginning, behalf, chemical, Classification, commonly, compulsive, constant, controlled, criteria, dealing, EITF, eligible, endpoint, established, expand, eye, FAS, February, FIN, FSP, grew, guidance, implementation, interested, Issue, leasing, Measurement, nicotine, nonfinancial, obesity, open, oversee, overseeing, participate, permit, ratified, referred, remain, remained, retained, statute

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CPRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification Required by 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

I, Jack Weinstein as Principal Financial Officer of Catalyst Pharmaceutical Partners, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2009 (the “Report”), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 11, 2009		/s/ Jack Weinstein
		Jack Weinstein
		Chief Financial Officer
		(Principal Financial Officer)